Early experiences with usage of long‐acting injectable cabotegravir among adults in rural Ugandan and Kenyan communities: qualitative research from the SEARCH “Dynamic Choice HIV Prevention” intervention trials
Journal of the International AIDS Society · 2025-11 · 28 (11)
DOI: 10.1002/jia2.70059 ↗Kurz gefasst
Qualitative Studie in der Zeitschrift Journal of the International AIDS Society, online erschienen am 24.11.2025. Verfasst von Carol S Camlin und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Prevention Science, Department of Medicine, University of California, San Francisco (UCSF), San Francisco, California, USA. Hauptthemen laut MEDLINE: HIV Infections, Pre-Exposure Prophylaxis, Anti-HIV Agents, Pyridones. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Allergy and Infectious Diseases of the National Institutes of Health.
Abstract (Originalsprache)
Introduction
Despite oral HIV pre‐exposure prophylaxis (PrEP) effectiveness, uptake and adherence remains a challenge. Newer HIV prevention technologies, including long‐acting injectable cabotegravir (CAB‐LA), are promising for addressing known barriers to oral PrEP uptake and adherence, yet research remains limited on experiences with CAB‐LA among at‐risk adults in community settings. This descriptive qualitative study explored experiences with CAB‐LA among adults participating in the SEARCH Dynamic Choice HIV Prevention (DCP) trial in rural Kenya and Uganda, which evaluated HIV prevention uptake through a structured, person‐centred DCP model.
Methods
We conducted in‐depth semi‐structured interviews in July−October 2023 with a purposively selected sample of 47 DCP trial participants who initiated CAB‐LA and had at least two injections. Interviews explored participants’ reasons for choosing CAB‐LA and their experiences with the method. We also included 10 participants who subsequently discontinued CAB‐LA or switched to another method. Data were analysed using inductive coding, memoing and framework analysis.
Results
The 47 participants ranged from 20 to 59 years of age; 13 were men and 34 were women. Participants were enthusiastic about CAB‐LA. They perceived it as novel, efficacious and advantageous relative to oral daily PrEP, which had been hindered by stigma, interruptions due to work, family visits and travel, side effects, and pill attributes (size and smell). Two major advantages of CAB‐LA over PrEP were improved protection from HIV stigma and from HIV acquisition due to easier adherence. Participants felt CAB‐LA was clearly distinguishable from antiretroviral therapy and would not mark them (mistakenly) as living with HIV; among women, clandestine use to guard against stigma from family members was more achievable compared to oral PrEP. Appointments for injections were rare enough (monthly, then bimonthly) that they could be kept, especially with reminders from providers, although for some, unpredictable work and travel schedules hindered their uptake of CAB‐LA. Participants cited injection‐site pain as the main drawback.
Conclusions
CAB‐LA overcame several known barriers to HIV prevention uptake and adherence for women and men. In contexts of continued HIV‐related stigma, CAB‐LA met some participants’ preferences for a product that permitted prevention to be visibly distinguishable from treatment, enabling HIV prevention uptake to feel safer. Moreover, adherence was more easily achieved with CAB‐LA compared to PrEP, boosting confidence in prevention efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Prevention Science, Department of Medicine, University of California, San Francisco (UCSF), San Francisco, California, USA.
- Obstetrics, Gynecology & Reproductive Sciences, University of California, San Francisco (UCSF), San Francisco, California, USA.
- Kenya Medical Research Institute (KEMRI), Kisumu, Kenya.
- Infectious Diseases Research Collaboration, Kampala, Uganda.
- Berkeley, Biostatistics, Epidemiology, and Computational Precision Health, University of California, Berkeley, California, USA.
- ViiV Healthcare, Washington, DC, USA.
ORCID-Profile: Carol S Camlin, Lawrence Owino, Gabriel Chamie, James Ayieko, Diane V Havlir
Förderung
- National Institute of Allergy and Infectious Diseases of the National Institutes of Health
Zitieren
APA
Camlin, C. S., Onyango, A., Johnson-Peretz, J., Akatukwasa, C., Arunga, T. O., Owino, L., Atwine, F., Byamukama, A., Mutabazi, A., Balzer, L. B., Czarnogorski, M., Kakande, E., Sunday, H., Chamie, G., Ayieko, J., Petersen, M., Sutter, N., Kamya, M. R., Havlir, D. V., & Kabami, J. (2025). Early experiences with usage of long‐acting injectable cabotegravir among adults in rural Ugandan and Kenyan communities: qualitative research from the SEARCH “Dynamic Choice HIV Prevention” intervention trials. Journal of the International AIDS Society, 28(11). https://doi.org/10.1002/jia2.70059
Vancouver
Camlin CS, Onyango A, Johnson-Peretz J, Akatukwasa C, Arunga TO, Owino L, et al. Early experiences with usage of long‐acting injectable cabotegravir among adults in rural Ugandan and Kenyan communities: qualitative research from the SEARCH “Dynamic Choice HIV Prevention” intervention trials. Journal of the International AIDS Society. 2025;28(11). doi:10.1002/jia2.70059
BibTeX
@article{Camlin2025,
author = {Camlin, Carol S and Onyango, Anjeline and Johnson-Peretz, Jason and Akatukwasa, Cecilia and Arunga, Titus O and Owino, Lawrence and Atwine, Frederick and Byamukama, Ambrose and Mutabazi, Andrew and Balzer, Laura B and Czarnogorski, Maggie and Kakande, Elijah and Sunday, Helen and Chamie, Gabriel and Ayieko, James and Petersen, Maya and Sutter, Nicole and Kamya, Moses R and Havlir, Diane V and Kabami, Jane},
title = {Early experiences with usage of long‐acting injectable cabotegravir among adults in rural Ugandan and Kenyan communities: qualitative research from the SEARCH “Dynamic Choice HIV Prevention” intervention trials},
journal = {Journal of the International AIDS Society},
year = {2025},
volume = {28},
number = {11},
doi = {10.1002/jia2.70059}
}
EUVIMED